Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation | PLOS ONE
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases | Arteriosclerosis, Thrombosis, and Vascular Biology
Apixaban Impurity C | CAS:503614-91-3 | MOLCOO CHEMICAL
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach | PLOS ONE